STARBOARD Extends Median PFS to 33 Months in Melanoma
The randomized phase 3 STARBOARD trial reported 33.0-month median PFS with encorafenib, binimetinib and pembrolizumab versus 3.4 months with pembrolizumab alone.
Topic
Pd 1 Immunotherapy
Topic
Topic
Topic
The randomized phase 3 STARBOARD trial reported 33.0-month median PFS with encorafenib, binimetinib and pembrolizumab versus 3.4 months with pembrolizumab alone.